publicações selecionadas
- COVID19 in Chronic Myeloid Leukemia patients from Latin America
- Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
- Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms
- Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
- Estudo de interrupção de imatinibe em pacientes portadores de leucemia mieloide crônica fase crônica, com resposta molecular sustentada ≤0,01% pela escala internacional
- Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
- Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
- Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia
- MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
